Log In
BCIQ
Print this Print this
 

SER-287

  Manage Alerts
Collapse Summary General Information
Company Seres Therapeutics Inc.
DescriptionEcobiotic microbiome therapeutic
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat inflammatory bowel disease (IBD); Treat mild to moderate ulcerative colitis (UC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,880.0M

$120.0M

$1,760.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/11/2016

$1,880.0M

$120.0M

$1,760.0M

Get a free BioCentury trial today